|1.||Peng, Fangyu: 3 articles (08/2015 - 04/2014)|
|2.||Muzik, Otto: 2 articles (08/2015 - 04/2014)|
|3.||Bauab, Tais M: 2 articles (01/2015 - 01/2015)|
|4.||Frem, Regina C G: 2 articles (01/2015 - 01/2015)|
|5.||Chorilli, Marlus: 2 articles (01/2015 - 01/2015)|
|6.||Ferreira, Ana M da Costa: 2 articles (01/2015 - 01/2015)|
|7.||Mauro, Antonio E: 2 articles (01/2015 - 01/2015)|
|8.||Lopes, Erica de O: 2 articles (01/2015 - 01/2015)|
|9.||Godoy Netto, Adelino V: 2 articles (01/2015 - 01/2015)|
|10.||Raddi, Maria S G: 2 articles (01/2015 - 01/2015)|
01/01/2015 - "Subsequently, groups of tumor implanted nude mice were treated with [(64)Cu]CuCl2 to simulate single- and multiple-dose therapy protocols, and results were analyzed to estimate therapeutic efficacy. "
01/01/2015 - "To evaluate the potential theranostic role of [(64)Cu]CuCl2 in GBM, the present work reports results from a preclinical study carried out in a xenografted GBM tumor mouse model. "
05/01/2014 - "Radionuclide treatment studies showed that the tumor growth in both the B16F10 and the A375M models under (64)CuCl2 treatment were much slower than that of the control group. "
08/01/2006 - "Cytotoxicity studies with seven different human tumor cell lines in vitro showed that the most active 2-(4,5-dihydro-1H-imidazol-2-yl)-5-nitro-1H-benzimidazole CuCl2 complex 10 inhibited the growth of cancer cells with IC50 between 4.76 and 10.84 microM."
05/01/2014 - "In vivo (64)CuCl2 PET imaging demonstrated that both B16F10 and A375M tumors were clearly visualized. "
|2.||Body Weight (Weight, Body)
11/01/1994 - "LEA rats (female, five weeks old) were injected subcutaneously with CuCl2 daily at a dose of 3 mg Cu/kg body weight for 2, 4, 6, and 9 days. "
01/01/1991 - "Male weanling Fischer rats were injected ip once daily with either 12.5 mg/kg body weight cupric chloride or 2 ml/kg body weight saline for up to 70 days. "
07/01/1981 - "A single intraperitoneal injection of cupric chloride, 10 micrograms/g body weight, resulted in an improvement of clinical symptoms and prevention of neuronal degeneration. "
03/11/2012 - "To evaluate the potential adverse health impact/immunotoxicological effects of this metal in situ due to over exposure, Swiss albino mice were treated (via intraperitoneal injections) with copper (II) chloride (copper chloride) at doses of 0, 5, or 7.5 mg copper chloride/kg body weight (b.w.) twice a week for 4 wk; these values were derived from LD₅₀ studies using copper chloride doses that ranged from 0 to 40 mg/kg BW (2×/wk, for 4 wk). "
01/01/1989 - "ICO:WIST rats were pretreated over 20 days, using oral administration of subtoxic doses of 1.5 mg/kg body weight of phenylmercury acetate (PMA) 15 mg/kg of CdCl2 and 15 mg/kg of CuCl2, to investigate correlations between nephrotoxic effects of PMA, on the one hand, and buildup through various extraneous substances of adaptive reactivity, on the other. "
|3.||Prostatic Neoplasms (Prostate Cancer)
07/01/2015 - "The preliminary results of this study show a high uptake of (64)CuCl2 in PC and involved regional lymph nodes indicating to a great potential of (64)CuCl2 PET/CT for primary staging of patients with prostate cancer."
07/01/2015 - "In this study, we aimed to look at the possible role of (64)CuCl2 PET/CT in staging of patients with prostate cancer (PC). "
04/01/2014 - "Human prostate cancer xenografts with increased (64)Cu radioactivity were visualized previously by PET using (64)CuCl2 as a radiotracer ((64)CuCl2 PET). "
03/15/2004 - "Furthermore, proteasome inhibition and apoptosis induction were detected in prostate cancer cells treated with the ligand 8-OHQ alone following pre-treatment with copper(II) chloride. "
04/01/2014 - "Overall, data indicated that hCtr1 is a promising theranostic target, which can be further developed for metabolic imaging of prostate cancer using (64)CuCl2 PET/CT and personalized cancer therapy targeting copper metabolism."
|4.||Neurodegenerative Diseases (Neurodegenerative Disease)
|5.||Melanoma (Melanoma, Malignant)
05/01/2014 - "Two melanoma cell lines (B16F10 and A375M) that highly expressed CTR1 were then selected to study the uptake and efflux of (64)CuCl2. "
05/01/2014 - "This study aimed to evaluate the use of (64)CuCl2 as a theranostic agent for PET and radionuclide therapy of malignant melanoma. "
05/01/2014 - "The tumors can be successfully visualized by (64)CuCl2 PET and further treated by (64)CuCl2, highlighting the high potential of using (64)CuCl2 as a theranostic agent for the management of melanoma."
|3.||Pentachlorophenol (Sodium Pentachlorophenate)
|6.||copper transporter 1
|7.||9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)
|9.||Cadmium Chloride (Cadmium Dichloride)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Corneal Transplantation (Keratoplasty)